A Phase I Study of Vorinostat in Combination with Bortezomib in Patients with Advanced Malignancies

BACKGROUND: A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors. METHODS: Patients received vorinostat orally once daily on days 1–14...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Schelman, William R., Traynor, Anne M., Holen, Kyle D., Kolesar, Jill M., Attia, Steven, Hoang, Tien, Eickhoff, Jens, Jiang, Zhisheng, Alberti, Dona, Marnocha, Rebecca, Reid, Joel M., Ames, Matthew M., McGovern, Renee M., Espinoza-Delgado, Igor, Wright, John J., Wilding, George, Bailey, Howard H.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3901262/
https://ncbi.nlm.nih.gov/pubmed/24114121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-0029-6
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items